[vc_row][vc_column][vc_column_text css=”.vc_custom_1423847449119{margin-bottom: 40px !important;}”]

Caryn C. Borg-Breen, Ph.D.



Caryn is a founding partner of Green Griffith. She specializes in intellectual property law, concentrating in patent litigation and counseling related to pharmaceutical, biotechnology, medical device and chemical products.

Caryn has particular experience representing both plaintiffs and defendants in patent litigation and consultation arising under the Hatch-Waxman Act. She has a strong background in formulating trial strategies, serving as trial counsel in patent infringement litigation in the U.S. federal courts and contributing to appeals before the Federal Circuit.

Caryn advises pharmaceutical, biotechnology and chemical companies on freedom-to-operate, due diligence, licensing and prosecution issues, as well as inter partes review and post-grant review proceedings.

Caryn works closely with her clients to understand their business goals and develop a strategy that achieves those goals.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column width=”1/1″][vc_accordion style=”3″ active_tab=”false” collapsible=”yes”][vc_accordion_tab title=”HONORS”][vc_column_text css=”.vc_custom_1452103235250{padding-right: 25px !important;padding-left: 40px !important;}”]

  • Recognized by Illinois Super Lawyers in Intellectual Property Litigation, 2016
  • Named in the “Illinois Rising Stars” list, as published in Illinois Super Lawyers, 2009, 2010, 2012, 2013, 2014, 2015
  • Honored in “Top Attorneys: Illinois Outstanding Young Woman Lawyers,” as published in Chicago Magazine, 2014

[/vc_column_text][/vc_accordion_tab][vc_accordion_tab title=”REPRESENTATIVE MATTERS”][vc_column_text css=”.vc_custom_1423176202529{padding-right: 25px !important;padding-left: 40px !important;}”]

  • Horizon Pharma Ireland Limited, et al. v. Watson Laboratories, Inc., 14-7992-NLH (D.N.J.) (diclofenac sodium topical – Pennsaid® 2%)
  • Horizon Pharma AG, et al. v. Watson Laboratories-Florida, 13-5124-JEI (D.N.J.) (delayed release prednisone – Rayos®)
  • Helsinn Healthcare SA et al. v. Cipla Ltd., 14-427-GMS (D.Del.) (palonosetron HCl injection – ALOXI®)
  • Pfizer Inc. et al. v. Lupin Ltd., 12-811-SLR (D.Del.) (desvenlafaxine – Pristiq®)
  • Warner Chilcott Co., LLC v. Lupin Ltd., 11-5048-JAP (D.N.J.) (norethindrone acetate/ethinyl estradiol – Lo Loestrin® Fe)
  • AstraZeneca AG, et al. v. Lupin Ltd., et al., 11-4275-JAP (D.N.J.) (naproxen/esomeprazole – Vimovo®)
  • Pfizer Inc. et al., v. Lupin Ltd. et al., 09-309-GMS (D.Del.) (pregabalin – Lyrica®)
  • Shire Canada Inc., et al. v. Natco Pharma Limited, 09-3165-JDG (S.D.N.Y.)
  • Eli Lilly & Co., et al. v. APP Pharmaceuticals, LLC, 08-0384-GMS (D.Del.) (pemetrexed – Alimta®)
  • Wyeth v. Lupin Ltd., et al., 07-0632-WDQ (D.Md.) (venlafaxine – Effexor XR®)
  • AstraZeneca AB, et al. v. Dexcel Ltd., et al., 06-358-SLR (D.Del.) (omeprazole – Prilosec OTC®)